Paper Details

  1. Home
  2. Paper Details

[Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].

Author: Bender-GötzeC, CreutzigU, EbellW, FriedrichW, GratwohlA, HeyenP, KlingebielT, SchmidtH, Stollmann-GibbelsB, SuttorpM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 16 patients with acute myeloid leukemia (AML) compared the outcomes of allogeneic bone marrow transplantation (BMT) to standard chemotherapy (CT-MC). Both treatments resulted in similar outcomes, with comparable rates of relapse and treatment-related deaths. The 9-year event-free survival rate was similar for both groups (73% for BMT and 67% for CT-MC). However, BMT was associated with more side effects, including long-term complications. The study concluded that there was no significant advantage to BMT for patients in their first complete remission. The study recommends that only high-risk patients receive BMT as soon as possible after achieving remission.
Paper Details　
Original Abstract of the Article :
16 patients of studies AML-BFM-83 and -87 with allogeneic bone marrow transplantation (BMT) in first complete remission (CR) were compared with matched controls with postremission chemotherapy (CT-MC). CT-MC were selected from 250 non-grafted patients with a minimum of remission duration correspondi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-2007-1025355

データ提供：米国国立医学図書館（NLM）

Chemotherapy versus Bone Marrow Transplantation: A Tale of Two Therapies for Acute Myeloid Leukemia

This study compares the outcomes of chemotherapy alone versus allogeneic bone marrow transplantation in children with acute myeloid leukemia (AML) who have achieved first complete remission. The researchers investigated the long-term efficacy and safety of both treatment approaches.

Navigating the Complexities of AML Treatment: A Desert of Diverse Options

The study found that both chemotherapy alone and allogeneic bone marrow transplantation had comparable long-term outcomes in terms of relapse rates and event-free survival. However, the study also highlighted that bone marrow transplantation was associated with higher rates of both early and late toxicities.

A Balanced Approach to AML Treatment: Finding the Right Path for Each Child

This research underscores the importance of carefully considering the risks and benefits of each treatment option for children with AML. The study suggests that allogeneic bone marrow transplantation may be most appropriate for high-risk patients, while chemotherapy alone may be sufficient for patients with lower risk factors.

Dr.Camel's Conclusion

AML treatment is a complex journey, and the choice between chemotherapy and bone marrow transplantation is not always straightforward. This research sheds light on the relative benefits and risks of each option, reminding us that finding the right path requires careful consideration and personalized decision-making.

Date :
  1. Date Completed 1992-10-08
  2. Date Revised 2007-11-15
Further Info :

Pubmed ID

1518260

DOI: Digital Object Identifier

10.1055/s-2007-1025355

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.